

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Impact of the COVID-19 pandemic on ongoing health research: an ad hoc survey among investigators in Germany

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-049086
Article Type:	Original research
Date Submitted by the Author:	04-Feb-2021
Complete List of Authors:	Bratan, Tanja; Fraunhofer Institute for Systems and Innovation Research ISI, Competence Center Emerging Technologies Aichinger, Heike; Fraunhofer Institute for Systems and Innovation Research ISI, Competence Center Emerging Technologies Brkic, Nicole; Fraunhofer Institute for Systems and Innovation Research ISI, Competence Center Emerging Technologies Rueter, Jana; University of Regensburg Apfelbacher, Christian; Otto von Guericke Universität Magdeburg, Institute of Social Medicine and Health Systems Research, Faculty of Medicine Loss, Julika; University of Regensburg, Medical Sociology; Robert Koch Institute
Keywords:	COVID-19, STATISTICS & RESEARCH METHODS, Information technology < BIOTECHNOLOGY & BIOINFORMATICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Impact of the COVID-19 pandemic on ongoing health research: an ad hoc survey among investigators in Germany

Tanja Bratan¹, Heike Aichinger¹, Nicole Brkic¹, Jana Rueter², Christian Apfelbacher³, Julika Loss^{2,4}

Author affiliations

1 Fraunhofer Institute for Systems and Innovation Research ISI, Karlsruhe, Germany

2 Medical Sociology, Department for Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany

3 Institute of Social Medicine and Health Systems Research, Otto von Guericke University Magdeburg, Magdeburg, Germany

4 Robert Koch Institute, Berlin, Germany

1. Correspondence to Dr Bratan; tanja.bratan@isi.fraunhofer.de

Abstract

Objectives To gain insights into the impact of the COVID-19 pandemic on ongoing health research projects, using projects from a selected funding programme in Germany as an example.

Design Online survey

Setting Lockdowns and social distancing policies impact upon clinical and public health research in various forms, especially if unrelated to COVID-19. Research institutions have reduced onsite activities, data is often collected remotely, and during the height of the crisis, clinical researchers were partially forced to abandon their projects in favour of front-line care and crisis response.

Participants 120 investigators of health research projects across Germany, performed between 15 and 25 May 2020.

Results The response rate (78%) showed that the survey generated significant interest among investigators. 85 responses were included for analysis, and the majority of investigators (93%) reported that their projects were affected by the pandemic, with many (80%) stating that data collection was not possible as planned, and they could not carry out interventions as planned (67%). Other impacts were caused by staff being unavailable, for example through child or elder care commitments or because of COVID-19 quarantine or illness. Investigators also reported that

1
2
3 publications were delayed or not feasible at all (56%), and some experienced problems with PhD
4 or Masters theses (18%). The majority of investigators had mitigation strategies in place such as
5 adjustment of data collection methods using digital tools (46%) or of project implementation in
6 general (46%), others made changes in research design or research questions (27%).
7
8
9

10 **Conclusions** The COVID-19 pandemic has severely impacted upon health research projects. The
11 main challenge is now to mitigate negative effects and to improve long-term resilience in health
12 research. The pandemic has also acted as a driver of innovation and change, for example by
13 accelerating the use of digital methods.
14
15
16
17
18
19

20 **Strengths and limitations of this study**

- 21 • To our knowledge, this is the first study investigating the impact of the COVID-19
22 pandemic on non COVID-19 health research projects, mitigation strategies employed by
23 investigators and needs for support.
- 24 • The sample is representative of the projects from the “Healthy - for a lifetime” funding
25 programme in Germany, which includes different types of health research projects and
26 involves different population groups.
- 27 • We were not able to clearly distinguish the effects on different types of projects (clinical
28 studies, observational studies, secondary data analyses etc.), because a small number of
29 investigators led more than one project and were not asked to report on each project
30 individually.
- 31 • The survey presents a snapshot of the situation in May 2020. To assess effects more
32 widely as well as long-term impacts on projects, the survey would need to be repeated.
33
34
35
36
37
38
39
40
41
42
43
44

45 **Introduction**

46
47 Since its outbreak in Wuhan in the People’s Republic of China at the end of 2019, the novel
48 coronavirus (severe acute respiratory syndrome corona virus 2, SARS-CoV-2) has rapidly spread
49 from its origin in the Hubei province to the rest of the world. It causes COVID-19 disease,
50 primarily affecting the respiratory system, with evidence of the effects on other organs and
51 systems also emerging. COVID-19 was declared a pandemic by the World Health Organization
52 (WHO) in March 2020 (1). The virus is spread from person to person through direct contact and
53 droplets (2) Subsequently, governmental responses worldwide have focused on mitigation
54 strategies such as social distancing, travel and movement restrictions, school closures, restricting
55
56
57
58
59
60

1
2
3 group and mass gatherings, up to the banning of public transport and lockdown of offices,
4 services and industries (3, 4, 1).

5
6
7 In most countries, these restrictions have disrupted people's lives and work in an unprecedented
8 way (5, 6). The pandemic has also impacted upon clinical and public health research in various
9 forms. On the one hand, the pandemic has placed scientific virologists, epidemiologists and
10 pneumologists at the forefront of COVID-19 research, and the number of academic publications
11 on COVID-19 is soaring (7). On the other hand, maintaining clinical, health services research and
12 public health studies is considerably impeded by lockdowns and social distancing policies. Many
13 research institutions have severely reduced onsite research (8), research activities have to be
14 performed remotely (especially research unrelated to COVID-19), and during the height of the
15 crisis clinical research programs were forced to abandon their schedules in favour of front-line
16 care and crisis response (9). Personal contacts with study participants and meetings among
17 research partners needed to be cancelled (8) or restricted.

18
19
20 This is also a set-back for public health and health services research. The strengthening of
21 diversity aspects as well as patient and civil rights over the past decades has transformed health-
22 related research: patient and public involvement in the planning and evaluation of clinical studies
23 and in health promotion have evolved to be the gold standard (10). Studies now prefer 'real life',
24 complex interventions engaging multiple stakeholders and partners in settings and health care
25 institutions (11). In order to assess the effectiveness of these multi-level interventions, mixed-
26 method designs have become increasingly popular, as they combine standardised measurements
27 and surveys with intensive qualitative data collection methods such as interviews and focus group
28 discussions (12–14).

29
30
31 These achievements in health-related research may have now made this kind of research
32 particularly vulnerable to social distancing measures and stay-at-home policies. Settings such as
33 nursing homes or schools cannot be approached easily anymore, participatory in-person meetings
34 with stakeholders, patients or citizens are not possible or made difficult, as are face-to-face data
35 collection methods. Inouye et al., report that field researchers may have to abandon an entire field
36 season due to bans on traveling and recruiting, and thereby lose irreplaceable data (15).

37
38
39 In addition, parents face novel challenges induced by closures of schools and day care centres, as
40 they need to devote time to looking after and home schooling their children and doing household
41 chores. Combining child care needs with remote academic working can prove difficult, if not
42 impossible in many cases (16, 17). This may further slow health-related research.

43
44
45 Few editorials and opinion pieces have raised awareness for the potentially substantial constraints
46 that the COVID-19 pandemic places upon the efficiency of ongoing scientific proceedings (8, 16,
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 15, 9) but empirical studies exploring or quantifying the challenges and needs of researchers
4 engaged in ongoing health research unrelated to COVID-19 are lacking to date.

5
6
7 Therefore, we intended to understand

- 8
9 - if, and how, non-COVID-19 related health research is affected by the COVID-19
10 pandemic,
11
12 - what strategies are used by researchers to mitigate challenges and potential (academic)
13 damages to their projects.
14
15

16 We addressed these questions by surveying investigators who are responsible for research funded
17 by the funding programme “Healthy – for a lifetime”. This is a four year governmental funding
18 programme in Germany (2017 – 2021) with an emphasis on the development and evaluation of
19 new concepts for health promotion, prevention and care for different life phases.
20
21
22
23
24

25 **Methods**

26 *The funding programme “Healthy – for a lifetime”*

27
28 In Germany, the Federal Ministry of Education and Research is, apart from the German Research
29 Foundation, the main funding agency for research (18). In health, main funding activities relate to
30 preventing and tackling common diseases, health services research, prevention and nutrition
31 research and personalised medicine (19). In 2016, the Ministry launched the ‘Healthy - for a
32 lifetime’ funding programme (‘*Gesund – ein Leben lang*’) to better address the following groups:
33 children and young people, the working population, older people as well as men and women. For
34 the research initiative, the Federal Ministry has provided approximately 100 million euros in
35 funding to promote the development of new and effective concepts for health promotion,
36 prevention and care. In total, 174 single projects and subprojects as part of consortia are being
37 funded in 79 different German universities or research institutions. The funding programme
38 consists of projects in five funding areas: Gender health (n = 32), occupational health (n = 35),
39 child and youth health (n = 60), clinical studies in old age (n = 18) as well as healthcare and
40 nursing studies in old age (n = 29). The majority of these projects can be defined as health
41 services research or prevention research in the form of interventions (53%); fewer studies relate to
42 literature reviews and studies with existing data (20%), observational studies (17%) or
43 biomedical/ laboratory research (3%).
44
45
46
47
48
49
50
51
52
53
54
55

56
57 The survey presented in this study is part of an accompanying research project for the ‘Healthy –
58 for a lifetime’ initiative (GeLang-Bella¹), the aim of which is to establish networks between
59
60

¹ Project website <https://www.begleitforschung-bella.de/en>

1
2
3 projects of the funding programme, offer scientific support, and to develop standards for central
4 overarching themes such as participatory approaches, patient-related outcomes, or transfer of
5 research results to practice. Its advisory board includes several patient representatives.
6
7

8 *Participants*

9
10 We performed an ad-hoc single online survey among researchers responsible for projects funded
11 within the funding programme 'Healthy – for a lifetime'. All investigators who had agreed to
12 participate in the accompanying research project GeLang-BeLLa (N = 120) were sent an e-mail
13 invitation with a personalised link to the survey. Investigators who were in charge of more than
14 one project (n = 10) were only sent one link, and for their convenience were asked to jointly
15 consider all of their projects in their response.
16
17
18
19

20 *Patient and Public Involvement*

21
22 No patients or members of the public were involved in this research.
23
24

25 *The online survey*

26
27 The survey was implemented as an online version using EFS Questback and was available
28 between 15th and 29th May 2020. The email invitation to complete the survey was followed up
29 by two reminders. A multi-option structured response format was used. In addition, free text fields
30 were provided to allow participants to add individual comments. The survey consisted of five
31 items enquiring (1) How the pandemic impacted on project implementation, process, and results,
32 (2) which specific (organisational, personal,...) conditions had caused this impact, (3) whether
33 academic output was compromised, i.e. concerning publications or master's or doctoral theses, (4)
34 which type of mitigation strategies had been implemented, and (5) whether there was a need for
35 specific support measures from the accompanying research project.
36
37
38
39
40
41

42 *Statistical analysis*

43
44 Data generated were analysed descriptively using Microsoft Excel. All variables were categorical,
45 hence counts and percentages were computed.
46
47

48 *Ethical considerations*

49
50 All 144 principal investigators of the 174 studies (some lead two or more studies, see above) were
51 asked to give informed consent for data collection and data storage for the accompanying research
52 project, including the consent to (a) be sent an online questionnaire, to (b) have the questionnaire
53 data analysed and saved. 120 principal investigators gave their written consent and were included
54 in the study. All questionnaires were de-identified by an independent trust centre before analysis.
55
56
57
58
59 The study was approved by the Ethics Committee of the University of Regensburg (19-1630-101).
60

The online workshop

1
2
3 A one-hour online workshop open to all interested investigators from the 'Healthy - for a lifetime'
4 funding programme was held on 28 May 2020. Thirty-two investigators participated in the virtual
5 event. They were presented with the results from the survey and asked to discuss them. The
6 workshop was minuted, and the minutes were analysed with regard to (a) confirmation of
7 presented study results, and (b) additional aspects that were brought up in response to the research
8 questions, given changes in COVID-19 mitigation policies that have emerged within the timespan
9 after the survey.
10
11
12
13
14

15 **Results**

16 *Sample*

17
18
19
20 Out of the 120 investigators who were invited to participate, 93 (78%) completed the
21 questionnaire. 8 responses were excluded from the sample because the projects had already ended
22 and could therefore not have been affected by the pandemic, which led to sample of 85 (71%)
23 questionnaires for analysis.
24
25

26
27 All funding areas are represented in the survey, with child and youth health projects most
28 prevalent. The distribution across the different funding areas broadly matches the overall
29 distribution of all funded projects, with gender projects and clinical studies in old age being
30 slightly underrepresented in our sample and healthcare and nursing studies in old age being very
31 slightly overrepresented. A small number of respondents were unsure which funding area their
32 project could be assigned to.
33
34
35
36

37 *Impact of the COVID-19 pandemic on research*

38
39
40 The vast majority of investigators reported that their projects were at least partially affected by the
41 pandemic, either because implementation was being impeded through the crisis (84%), or because
42 it was suspended (18%) (Figure 1).
43
44
45
46

47
48 Figure 1: Perceived effects of the COVID-19 pandemic on project implementation, N=85,
49 multiple answers possible
50
51
52

53
54 Those respondents who reported an effect on project implementation (93%), were asked for the
55 causes (Figure 2). The most frequently cited barriers to continuing research projects were
56 difficulties in data collection procedures (80%), and failure to implement planned interventions
57 (67%). Also, staff shortages due to the pandemic were reported, e.g. due to child care
58 commitments during the lockdown resulting from the closure of child care facilities or because of
59 elder care commitments (38%), due to COVID-19 quarantine and disease (11%) or because all
60

1
2
3 project work had been suspended because of official instructions (14%) or because staff had been
4 assigned to other tasks, e.g. clinical work (9%).
5
6
7
8
9

10
11 Figure 2: Causes of research impediments, N=79, multiple answers possible
12

13 Additional free text responses indicated further problems with recruitment of study participants,
14 which proved more difficult during the pandemic, had been put on hold or ended ahead of time (n
15 = 4). Data collection was described as being more difficult or of lower quality (n=3). Practical
16 adjustments such as shifting tasks between project partners, working from home and virtual
17 meetings replacing travel were also reported (n=6), while others cited difficulties caused by
18 working from home, which included access to data or technical infrastructures (n=2). Lacking
19 possibilities of validating findings through conference presentations were also mentioned (n=1)
20

21 The COVID 19 pandemic also impacted on scientific outputs and academic careers; for example,
22 more than half of participants stated that publications were delayed or could not be realised
23 (56%). Difficulties with continuing PhD and master's theses were also reported (18%). Figure 3
24 shows more details.
25
26
27
28
29
30
31
32
33
34

35 Figure 3: Influence of the pandemic on scientific and/or academic progress, N=85, multiple
36 answers possible
37

38 The majority of researchers have reacted to the restrictions caused by the pandemic with
39 mitigation strategies. They modified their data collection methods (46%, e.g. by employing
40 Internet-based access to study participants) or made adjustments in project implementation (46%).
41 In some projects, the research concept including the research questions were adjusted, sometimes
42 to include COVID-19 related topics (27%). However, some projects (18%) did not employ
43 mitigation strategies, sometimes because no suitable measures were available. See Figure 4 for
44 more details.
45
46
47
48
49
50
51
52
53
54

55 Figure 4: Mitigation strategies used to deal with restrictions caused by the pandemic, N=85,
56 multiple answers possible
57

58 In terms of support requirements, some researchers expressed an interest in sharing know-how
59 with the other funded projects about digital communication tools (21%) and enabling participation
60

1
2
3 digitally, e.g. in terms of organisational and moderation skills (19%). This is presented in Figure
4
5 5.

6
7
8
9 Figure 5: Need for support from the accompanying research project, N=86, multiple answers
10 possible

11 *Validation through online workshop*

12
13
14
15 The discussions documented during the workshop confirmed the survey results and highlighted
16 the immense effect the pandemic has had on many health research projects not related to COVID-
17 19. Concerns were raised about the ability to re-start interventions, for example in the case of
18 workplace interventions when staff were working remotely or were on reduced hours.

19
20
21
22 Investigators of projects that were able to continue implementation were concerned about the
23 validity of their research in the face of deviations from study protocols that had been necessary
24 during the pandemic. It was also pointed out that some projects, e.g. about mental health, had
25 defined patient endpoints such as loneliness and depression, which were now severely affected by
26 the pandemic, so the comparability of the data to earlier results may be reduced.

27
28
29
30
31 Organisational issues regarding data collection and implementation of interventions during the
32 pandemic were raised, e.g. the need to inform participants about risk of infection, hygiene
33 requirements or liability. Difficulties of elderly participants with online data collection were
34 reported as a further practical challenge.
35
36
37
38
39

40 **Discussion**

41 *Principal findings*

42
43
44
45 Our findings show that the COVID-19 pandemic has had a severe impact on the vast majority of
46 93 heterogeneous health research projects of the “Healthy - for a lifetime” funding programme.
47 The programme is not related to COVID-19 research, and most projects were unable to continue
48 their work as planned. They were impeded in their recruitment of participants, implementation of
49 interventions or data collection. A lack of staff availability due to private or other professional
50 commitments or as a result of COVID-19 quarantine or illness were also observed by half of the
51 investigators surveyed. Several participants reported that projects had to be suspended
52 temporarily, and at the time of the survey, it was not clear whether they could be resumed in the
53 near future. Investigators were creative in developing mitigation strategies for restrictions in data
54 collections, with many drawing on digital communication, but this was not an option for all
55
56
57
58
59
60

1
2
3 projects. A quarter of participants stated that they bridged the imposed suspension in their projects
4 by adjusting their research, including pursuing novel COVID-19-related research. Investigators
5 also expressed a need for exchange on digital communication as well as guidance regarding issues
6 such as hygiene and participation. Methodological issues related to deviation from study protocols
7 or validity of mid-study changes in data collection methods. This also raised concerns as to
8 whether the data would eventually qualify for publication and further scientific exploitation, or
9 whether they would ultimately need to be abandoned.

15 *Meaning of study and implications for policy and practice*

17 Due to the ongoing need for social distancing, personal contact with study participants and
18 therefore resumption of regular data collection and implementation of interventions is likely to
19 remain difficult. Also, there is the risk of new waves of infections and either local or general lock-
20 downs due to SARS-CoV-2, but possibly in the future also due to other pandemics. Therefore,
21 future strategies for planning, implementing and funding health research need to incorporate the
22 possibility of potential disruptions and restrictions inflicted by pandemics and infection control
23 measures. The importance of research, especially in crisis situations, as well as the need for new
24 paradigms and models of resilient and efficient research has been highlighted in the literature (20,
25 21). Therefore, it seems important to not only handle the current challenges, but also to plan for
26 long-term approaches preventing or taking into consideration these challenges for future research.
27 Our study raises the following important questions: a) How can progress made with participation
28 in health research be maintained despite difficulties and uncertainties about the future? b) How
29 can resilience be built into study protocols to ensure that they can be adapted if necessary and data
30 already collected is not lost, and at the same time protocols remain methodologically robust? c)
31 How can different intervention and data collection methods be meaningfully combined and biases
32 introduced be accounted for? d) How can funding instruments be designed to accommodate
33 changes more easily and, e) How can funders support investigators during crises such as
34 pandemics?

35
36
37 The pandemic is currently changing the way scientific knowledge is being produced (22), in fact it
38 is accelerating a trend that has already been underway: The use of digital tools had been
39 increasing gradually (23, 24) , and during the pandemic, with often no other alternatives being
40 available, it has surged (25). While the pandemic undeniably poses many challenges to health
41 research projects, its silver lining may be a chance to make a leap in digital communication and
42 participation as well as better resilience at both the research and the funding side. This should be
43 accompanied by a thorough investigation of the strengths and weaknesses as well as the
44 comparability of different tools for interventions and data collection methods. Existing findings
45 on the comparison of analogue and digital data collection methods are sparse and limited in scope,
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 but so far indicate that there are no far-reaching differences (26–31). More research is required
4 regarding issues such as acceptance, reach and over-/ underrepresentation of different groups,
5 usability in different settings and for different topics. During data analysis, the influence of
6 changes in collection methods and other deviations from study protocols as well as missing
7 information need to be considered. Descriptions should delineate which of these irregularities are
8 likely to be a result of the COVID-19 pandemic and which uncertainties remain (32).

9
10
11 Funders should consider granting extensions to projects if these face delays because of the
12 pandemic, and allow for adjustments in research design and research questions. Changes to
13 funding itself may also be needed. To prepare for ongoing restrictions, further lockdowns or other
14 pandemics, policy makers and funders could introduce more flexible funding instruments.
15 Research that generates evidence about the validity and scientific rigour of digital methods or
16 about the combination of digital and traditional methods will be needed to accompany the shift to
17 a “new normality” in research, and it will also be a task for policy makers to ensure research
18 priorities are set accordingly.

19
20
21 Researchers will be required to continue experimenting with new approaches, assessing their
22 usefulness, reflecting on their findings and sharing their insights. The scientific community at
23 large will have to deal with results of research that have taken place under different circumstances
24 than usual, and maybe with methodologic compromises. Consensus will be needed about how
25 these findings can be meaningfully integrated with other scientific outcomes, both in terms of
26 comparison to existing findings and in terms of research validation. Ultimately, it is a joint
27 responsibility of policy makers, researchers, health professionals and funders to ensure that
28 research funding is spent efficiently and effectively. The pandemic has changed the way in which
29 scientific knowledge is produced, and some of the changes may be permanent, which will
30 ultimately require adaptations to what constitutes good scientific practice.

31 32 33 34 35 36 37 38 39 40 41 42 43 44 *Strengths and weaknesses*

45
46 To our knowledge, our study is the first ever investigation into the effects of the pandemic on
47 health research projects not related to COVID-19. It uses a representative sample of
48 heterogeneous projects from the “Healthy - for a lifetime” funding programme in Germany,
49 therefore giving important insights into the impact on health research in general. However, it only
50 presents a snapshot of the situation in May 2020, and captured the experiences of a limited
51 number of investigators. Due to the dynamics in the COVID-19 pandemic and infection control
52 measures, restrictions in project work and data collection processes vary significantly over time.
53 Therefore, it would be helpful to repeat the survey at certain intervals.

1
2
3 The research projects included in the study covered a wide range of topics, addressed target
4 groups, and study types. However, due to the overall focus of the funding programme, there was a
5 predominance of intervention projects in prevention and health services research; biomedical
6 research accounted for only a minority of projects. Among biomedical, laboratory-based studies,
7 regulations about social distancing may have a different influence (e.g. by rendering access to labs
8 difficult, rather than preventing contact to patients or participants). Still, our survey results
9 highlight the range and extent of challenges imposed upon health research.
10
11
12
13
14
15
16
17

18 **Conclusions**

19
20 The disruption of health research projects caused by the COVID-19 pandemic has been severe and
21 calls for short-term measures to limit damage to projects and to participation in health research in
22 general, but also the development of long-term strategies to improve the resilience of research
23 against imponderables posed by pandemics. Both require flexibility from policy makers, funders
24 and researchers as well as insights and guidance from the scientific community.
25
26
27
28
29
30

31 **What is already known on this topic**

- 32 • To our knowledge, there has been no previous research on the impact of the COVID-19
33 pandemic on ongoing health research projects.
34
35
36

37 **What this study adds**

- 38 • The study sheds light on how ongoing health research projects in Germany have been
39 affected by the COVID-19 pandemic. It also investigates what mitigation strategies have
40 been put in place, what issues could not be resolved and what challenges and opportunities
41 the current situation holds for policy makers, funders, researchers and the scientific
42 community at large.
43
44
45
46
47
48
49

50 **Footnotes**

51
52 **Contributors** TB, JL, CA, HA and JR designed the study. TB led its implementation and together
53 with JL wrote the initial draft of the article. All authors were involved in subsequent protocol
54 revisions. NB carried out the initial analysis of the data and all authors were involved in further
55 analysis.
56
57

58 **Funding** This work was supported by the German Ministry of Education and Research, grant
59 number 01GL1905B.
60

1
2
3 **Competing interests** None declared.
4

5 **Ethical approval** University of Regensburg Ethical Committee (19-1630-101).
6
7

8 **Data sharing statement** No additional data are available.
9

10
11 **Transparency declaration** TB affirms that the manuscript is an honest, accurate, and transparent
12 account of the study being reported; that no important aspects of the study have been omitted; and
13 that any discrepancies from the study as planned (and, if relevant, registered) have been
14 explained.
15

16
17 Dissemination to participants and related patient and public communities: Preliminary findings
18 have already been shared and discussed with investigators from the “Healthy - for a lifetime”
19 funding programme. The publication will also be disseminated among this group, the funding
20 body and beyond.
21

22
23 A preprint of this manuscript has been deposited at <https://www.medrxiv.org/>.
24


25 **Licence** The Corresponding Author has the right to grant on behalf of all authors and does grant
26 on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all
27 forms, formats and media (whether known now or created in the future), to i) publish, reproduce,
28 distribute, display and store the Contribution, ii) translate the Contribution into other languages,
29 create adaptations, reprints, include within collections and create summaries, extracts and/or,
30 abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution,
31 iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the
32 Contribution to third party material where-ever it may be located; and, vi) licence any third party
33 to do any or all of the above.
34
35
36
37
38
39
40
41
42

43 **References**

- 44
45 1. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G et al. COVID-19: towards
46 controlling of a pandemic. *The Lancet* 2020; 395(10229):1015–8.
47
- 48 2. WHO. Transmission of SARS-CoV-2: implications for infection prevention precautions: Scientific
49 Brief; 2020 [cited 2020 Jul 30]. Available from: URL: [https://www.who.int/news-](https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions)
50 [room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-](https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions)
51 [precautions](https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions).
52
53
- 54 3. Zhang SX, Wang Y, Rauch A, Wei F. Unprecedented disruption of lives and work: Health, distress
55 and life satisfaction of working adults in China one month into the COVID-19 outbreak. *Psychiatry Res*
56 2020; 288:112958.
57
- 58 4. Walensky RP, Del Rio C. From Mitigation to Containment of the COVID-19 Pandemic: Putting the
59 SARS-CoV-2 Genie Back in the Bottle. *JAMA* 2020.
60


- 1
2
3 5. Zhang Y, Ma ZF. Impact of the COVID-19 Pandemic on Mental Health and Quality of Life among
4 Local Residents in Liaoning Province, China: A Cross-Sectional Study. *Int J Environ Res Public Health*
5 2020; 17(7).
- 6
7 6. Cluver L, Lachman JM, Sherr L, Wessels I, Krug E, Rakotomalala S et al. Parenting in a time of
8 COVID-19. *The Lancet* 2020; 395(10231):e64.
- 9
10 7. Kambhampati SBS, Vaishya R, Vaish A. Unprecedented surge in publications related to COVID-19 in
11 the first three months of pandemic: A bibliometric analytic report. *J Clin Orthop Trauma* 2020.
- 12
13 8. Omary MB, Eswaraka J, Kimball SD, Moghe PV, Panettieri RA, Scotto KW. The COVID-19 pandemic
14 and research shutdown: staying safe and productive. *J Clin Invest* 2020.
- 15
16 9. Graham MM, Higginson L, Brindley PG, Jetly R. Feel Better, Work Better: The COVID-19
17 Perspective. *Can J Cardiol* 2020.
- 18
19 10. Callard F, Rose D, Wykes T. Close to the bench as well as at the bedside: involving service users in
20 all phases of translational research. *Health Expect* 2012; 15(4):389–400.
- 21
22 11. Tremblay M-C, Richard L. Complexity: a potential paradigm for a health promotion discipline.
23 *Health Promot Int* 2014; 29(2):378–88.
- 24
25 12. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating
26 complex interventions: the new Medical Research Council guidance. *BMJ* 2008; 337:a1655.
- 27
28 13. Bressan V, Bagnasco A, Aleo G, Timmins F, Barisone M, Bianchi M et al. Mixed-methods research
29 in nursing - a critical review. *J Clin Nurs* 2017; 26(19-20):2878–90.
- 30
31 14. Willis R, Evandrou M, Pathak P, Khambhaita P. Problems with measuring satisfaction with social
32 care. *Health Soc Care Community* 2016; 24(5):587–95.
- 33
34 15. Inouye DW, Underwood N, Inouye BD, Irwin RE. Support early-career field researchers. *Science*
35 2020; 368(6492):724–5.
- 36
37 16. Staniscuaski F, Reichert F, Werneck FP, Oliveira L de, Mello-Carpes PB, Soletti RC et al. Impact of
38 COVID-19 on academic mothers. *Science* 2020; 368(6492):724. Available from: URL:
39 [https://science.sciencemag.org/content/368/6492/724.1?fbclid=IwAR31Qq-VYfKlbrA3MrbH-](https://science.sciencemag.org/content/368/6492/724.1?fbclid=IwAR31Qq-VYfKlbrA3MrbH-7lrzCl4KvnpdFYdbgP0rO8wccoMtZHDN6-jyys)
40 [7lrzCl4KvnpdFYdbgP0rO8wccoMtZHDN6-jyys](https://science.sciencemag.org/content/368/6492/724.1?fbclid=IwAR31Qq-VYfKlbrA3MrbH-7lrzCl4KvnpdFYdbgP0rO8wccoMtZHDN6-jyys).
- 41
42 17. Alon T, Doepke M, Olmstead-Rumsey J, Tertilt M. *The Impact of COVID-19 on Gender Equality*.
43 Cambridge, MA; 2020.
- 44
45 18. Wang X, Di Liu, Ding K, Wang X. Science funding and research output: a study on 10 countries.
46 *Scientometrics* 2012; 91(2):591–9.
- 47
48 19. Federal Ministry of Health. Health Research [cited 2020 Aug 5]. Available from: URL:
49 <https://www.bmbf.de/en/health-research-2308.html>.
- 50
51 20. Weiner DL, Balasubramaniam V, Shah SI, Javier JR. COVID-19 impact on research, lessons learned
52 from COVID-19 research, implications for pediatric research. *Pediatr Res* 2020; 88(2):148–50.
- 53
54 21. Richardson SJ, Carroll CB, Close J, Gordon AL, O'Brien J, Quinn TJ et al. Research with older people
55 in a world with COVID-19: identification of current and future priorities, challenges and
56 opportunities. *Age Ageing* 2020.
- 57
58
59
60

- 1
2
3 22. Bayram M, Springer S, Garvey CK, Özdemir V. COVID-19 Digital Health Innovation Policy: A Portal
4 to Alternative Futures in the Making. *OMICS* 2020 [cited 2020 Jul 16].
5
- 6 23. Lo Iacono V, Symonds P, Brown DHK. Skype as a Tool for Qualitative Research Interviews.
7 *Sociological Research Online* 2016; 21(2):103–17.
8
- 9 24. Archibald MM, Ambagtsheer RC, Casey MG, Lawless M. Using Zoom Videoconferencing for
10 Qualitative Data Collection: Perceptions and Experiences of Researchers and Participants.
11 *International Journal of Qualitative Methods* 2019; 18:160940691987459.
12
- 13 25. Lupton D. Doing fieldwork in a pandemic (crowd-sourced document); 2020 [cited 10.8.20].
14 Available from: URL:
15 <https://docs.google.com/document/d/1clGjGABB2h2qbduTgfqribHmog9B6P0NvMgVuiHZCl8/edit?ts=5e88ae0a#>.
16
17
18
- 19 26. Belisario MJS, Jamsek J, Huckvale K, O'Donoghue J, Morrison CP, Car J. Comparison of self-
20 administered survey questionnaire responses collected using mobile apps versus other methods.
21 *Cochrane Database Syst Rev* 2015 [cited 2020 Jul 16]; (7):MR000042.
22
- 23 27. Barentsz MW, Wessels H, van Diest PJ, Pijnappel RM, Haaring C, van der Pol CC et al. Tablet, web-
24 based, or paper questionnaires for measuring anxiety in patients suspected of breast cancer:
25 patients' preferences and quality of collected data. *J Med Internet Res* 2014 [cited 2020 Jul 16];
26 16(10):e239.
27
28
- 29 28. Gwaltney CJ, Shields AL, Shiffman S. Equivalence of electronic and paper-and-pencil
30 administration of patient-reported outcome measures: a meta-analytic review. *Value Health* 2008
31 [cited 2020 Jul 16]; 11(2):322–33.
32
- 33 29. Morison T, Gibson AF, Wigginton B, Crabb S. Online Research Methods in Psychology:
34 Methodological Opportunities for Critical Qualitative Research. *Qualitative Research in Psychology*
35 2015 [cited 2020 Jul 16]; 12(3):223–32.
36
- 37 30. Janghorban R, Latifnejad Roudsari R, Taghipour A. Skype interviewing: the new generation of
38 online synchronous interview in qualitative research. *Int J Qual Stud Health Well-being* 2014 [cited
39 2020 Jul 16]; 9:24152.
40
- 41 31. Touvier M, Méjean C, Kesse-Guyot E, Pollet C, Malon A, Castetbon K et al. Comparison between
42 web-based and paper versions of a self-administered anthropometric questionnaire. *Eur J Epidemiol*
43 2010 [cited 2020 Jul 16]; 25(5):287–96.
44
45
- 46 32. Fleming TR, Labriola D, Wittes J. Conducting Clinical Research During the COVID-19 Pandemic:
47 Protecting Scientific Integrity. *JAMA* 2020 [cited 2020 Jul 16].
48
49
50
51
52
53
54
55
56
57
58
59
60




For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




For peer review only




For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



For peer review only



STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses

Continued on next page

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Impact of the COVID-19 pandemic on ongoing health research: an ad hoc survey among investigators in Germany

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-049086.R1
Article Type:	Original research
Date Submitted by the Author:	04-Nov-2021
Complete List of Authors:	Bratan, Tanja; Fraunhofer Institute for Systems and Innovation Research ISI, Competence Center Emerging Technologies Aichinger, Heike; Fraunhofer Institute for Systems and Innovation Research ISI, Competence Center Emerging Technologies Brkic, Nicole; Fraunhofer Institute for Systems and Innovation Research ISI, Competence Center Emerging Technologies Rueter, Jana; University of Regensburg Apfelbacher, Christian; Otto von Guericke Universität Magdeburg, Institute of Social Medicine and Health Systems Research, Faculty of Medicine Boyer, Lisa; University of Regensburg Loss, Julika; University of Regensburg, Medical Sociology; Robert Koch Institute
Primary Subject Heading:	Research methods
Secondary Subject Heading:	Public health
Keywords:	COVID-19, STATISTICS & RESEARCH METHODS, Information technology < BIOTECHNOLOGY & BIOINFORMATICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Impact of the COVID-19 pandemic on ongoing health research: an ad hoc survey among investigators in Germany

Tanja Bratan¹, Heike Aichinger¹, Nicole Brkic¹, Jana Rueter², Christian Apfelbacher³, Lisa Boyer², Julika Loss^{2,4}

Author affiliations

1 Fraunhofer Institute for Systems and Innovation Research ISI, Karlsruhe, Germany

2 Medical Sociology, Department for Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany

3 Institute of Social Medicine and Health Systems Research, Otto von Guericke University Magdeburg, Magdeburg, Germany

4 Robert Koch Institute, Berlin, Germany

1. Correspondence to Dr Bratan; tanja.bratan@isi.fraunhofer.de

Abstract

Objectives To gain insights into the impact of the COVID-19 pandemic on ongoing health research projects, using projects from a selected funding programme in Germany as an example.

Design Online survey and validation workshop.

Setting Lockdowns and social distancing policies impact upon clinical and public health research in various forms, especially if unrelated to COVID-19. Research institutions have reduced onsite activities, data is often collected remotely, and during the height of the crisis, clinical researchers were partially forced to abandon their projects in favour of front-line care.

Participants Survey: 120 investigators of health research projects across Germany, performed between 15 and 25 May 2020; workshop: 32 investigators, performed on 28 May 2020.

Results The response rate (78%) showed that the survey generated significant interest among investigators. 85 responses were included for analysis, and the majority of investigators (93%) reported that their projects were affected by the pandemic, with many (80%) stating that data collection was not possible as planned, and they could not carry out interventions as intended (67%). Other impacts were caused by staff being unavailable, e.g. through child or elder care commitments or because of COVID-19 quarantine or illness. Investigators also reported that

1
2
3 publications were delayed or not feasible at all (56%), and some experienced problems with PhD
4 or Masters theses (18%). The majority of investigators had mitigation strategies in place such as
5 adjustment of data collection methods using digital tools (46%) or of project implementation in
6 general (46%), others made changes in research design or research questions (27%).
7
8
9

10 **Conclusions** The COVID-19 pandemic has severely impacted upon health research projects. The
11 main challenge is now to mitigate negative effects and to improve long-term resilience in health
12 research. The pandemic has also acted as a driver of innovation and change, for example by
13 accelerating the use of digital methods.
14
15
16
17
18
19

20 **Strengths and limitations of this study**

- 21 • To our knowledge, this is the first study investigating the impact of the COVID-19
22 pandemic on ongoing non COVID-19 health research projects, mitigation strategies
23 employed by investigators and needs for support.
- 24 • The sample is representative of the projects from the “Healthy - for a lifetime” funding
25 programme in Germany, which includes different types of health research projects and
26 involves different population groups.
- 27 • We were not able to clearly distinguish the effects on different types of projects (clinical
28 studies, observational studies, secondary data analyses etc.), because a small number of
29 investigators led more than one project and were not asked to report on each project
30 individually.
- 31 • The survey presents a snapshot of the situation in May 2020. To assess effects more
32 widely as well as long-term impacts on projects, the survey would need to be repeated.
33
34
35
36
37
38
39
40
41
42
43
44

45 **Introduction**

46
47 Since its outbreak in Wuhan in the People’s Republic of China at the end of 2019, the novel
48 coronavirus (severe acute respiratory syndrome corona virus 2, SARS-CoV-2) has rapidly spread
49 from its origin in the Hubei province to the rest of the world. It causes COVID-19 disease,
50 primarily affecting the respiratory system, with evidence of the effects on other organs and
51 systems also emerging. COVID-19 was declared a pandemic by the World Health Organization
52 (WHO) in March 2020 (1). The virus is spread from person to person through direct contact and
53 droplets (2) Subsequently, governmental responses worldwide have focused on mitigation
54 strategies such as social distancing, travel and movement restrictions, school closures, restricting
55
56
57
58
59
60

1
2
3 group and mass gatherings, up to the banning of public transport and lockdown of offices,
4 services and industries (3, 4, 1).

5
6
7 In most countries, these restrictions have disrupted people's lives and work in an unprecedented
8 way (5, 6). The pandemic has also impacted upon clinical and public health research in various
9 forms. On the one hand, the pandemic has placed scientific virologists, epidemiologists and
10 pneumologists at the forefront of COVID-19 research, and the number of academic publications
11 on COVID-19 is soaring (7). On the other hand, maintaining clinical, health services research and
12 public health studies is considerably impeded by lockdowns and social distancing policies. Many
13 research institutions have severely reduced onsite research (8), research activities have to be
14 performed remotely (especially research unrelated to COVID-19), and during the height of the
15 crisis clinical research programs were forced to abandon their schedules in favour of front-line
16 care and crisis response (9). Personal contacts with study participants and meetings among
17 research partners needed to be cancelled (8) or restricted.

18
19
20 This is also a set-back for public health and health services research. The strengthening of
21 diversity aspects as well as patient and civil rights over the past decades has transformed health-
22 related research: patient and public involvement in the planning and evaluation of clinical studies
23 and in health promotion have evolved to be the gold standard (10). Studies now prefer 'real life',
24 complex interventions engaging multiple stakeholders and partners in settings and health care
25 institutions (11). In order to assess the effectiveness of these multi-level interventions, mixed-
26 method designs have become increasingly popular, as they combine standardised measurements
27 and surveys with intensive qualitative data collection methods such as interviews and focus group
28 discussions (12–14).

29
30
31 These achievements in health-related research may have now made this kind of research
32 particularly vulnerable to social distancing measures and stay-at-home policies. Settings such as
33 nursing homes or schools cannot be approached easily anymore, participatory in-person meetings
34 with stakeholders, patients or citizens are not possible or made difficult, as are face-to-face data
35 collection methods. Inouye et al., report that field researchers may have to abandon an entire field
36 season due to bans on traveling and recruiting, and thereby lose irreplaceable data (15).

37
38
39 In addition, parents face novel challenges induced by closures of schools and day care centres, as
40 they need to devote time to looking after and home schooling their children and doing household
41 chores. Combining child care needs with remote academic working can prove difficult, if not
42 impossible in many cases (16, 17). This may further slow health-related research.

43
44
45 Few editorials and opinion pieces have raised awareness for the potentially substantial constraints
46 that the COVID-19 pandemic places upon the efficiency of ongoing scientific proceedings (8, 16,
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 15, 9) but empirical studies exploring or quantifying the challenges and needs of researchers
4 engaged in ongoing health research unrelated to COVID-19 are lacking to date.

5
6
7 Therefore, we intended to understand

- 8
9 - if, and how, non-COVID-19 related health research is affected by the COVID-19
10 pandemic,
11
12 - what strategies are used by researchers to mitigate challenges and potential (academic)
13 damages to their projects.
14
15

16 We addressed these questions by surveying investigators who are responsible for research funded
17 by the funding programme “Healthy – for a lifetime”. This is a four year governmental funding
18 programme in Germany (2017 – 2021) with an emphasis on the development and evaluation of
19 new concepts for health promotion, prevention and care for different life phases.
20
21
22
23
24

25 **Methods**

26 *The funding programme “Healthy – for a lifetime”*

27
28
29
30 In Germany, the Federal Ministry of Education and Research is, apart from the German Research
31 Foundation, the main funding agency for research (18). In health, main funding activities relate to
32 preventing and tackling common diseases, health services research, prevention and nutrition
33 research and personalised medicine (19). In 2016, the Ministry launched the ‘Healthy - for a
34 lifetime’ funding programme (‘*Gesund – ein Leben lang*’) to better address the following groups:
35 children and young people, the working population, older people as well as men and women. For
36 the research initiative, the Federal Ministry has provided approximately 100 million euros in
37 funding to promote the development of new and effective concepts for health promotion,
38 prevention and care. In total, 174 single projects and subprojects as part of consortia are being
39 funded in 79 different German universities or research institutions. The funding programme
40 consists of projects in five funding areas: Gender health (n = 32), occupational health (n = 35),
41 child and youth health (n = 60), clinical studies in old age (n = 18) as well as healthcare and
42 nursing studies in old age (n = 29). The majority of these projects can be defined as health
43 services research or prevention research in the form of interventions (53%); fewer studies relate to
44 literature reviews and studies with existing data (20%), observational studies (17%) or
45 biomedical/ laboratory research (3%).
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The survey presented in this study is part of an evaluation for the ‘Healthy – for a lifetime’
4 initiative (GeLang-Bella¹), the aim of which is to establish networks between projects of the
5 funding programme, offer scientific support, and to develop standards for central overarching
6 themes such as participatory approaches, patient-related outcomes, or transfer of research results
7 to practice. Its advisory board includes several patient representatives.
8
9

10 11 *Participants*

12
13 We performed an ad-hoc single online survey among researchers responsible for projects funded
14 within the funding programme ‘Healthy – for a lifetime’. All investigators who had agreed to
15 participate in the evaluation project GeLang-BeLLa (N = 120) were sent an e-mail invitation with
16 a personalised link to the survey. For requesting informed consent from the investigators, the
17 project team had gathered names and contact details of investigators from publicly available
18 sources. Investigators who were in charge of more than one project (n = 10) were only sent one
19 link, and for their convenience were asked to jointly consider all of their projects in their response.
20 All investigators were invited to participate in the online workshop after completion of the survey
21 phase. They were also allowed to send members of their team if they wished.
22
23
24
25
26
27
28

29 *Patient and Public Involvement*

30 No patients or members of the public were involved in this research.
31

32 *The online survey*

33
34 The survey was implemented as an online version using EFS Questback and was available
35 between 15th and 29th May 2020. The email invitation to complete the survey was followed up
36 by two reminders. A multi-option structured response format was used. In addition, free text fields
37 were provided to allow participants to add individual comments. The survey consisted of five
38 items enquiring (1) How the pandemic impacted on project implementation, process, and results,
39 (2) which specific (organisational, personal,...) conditions had caused this impact, (3) whether
40 academic output was compromised, i.e. concerning publications or master’s or doctoral theses, (4)
41 which type of mitigation strategies had been implemented, and (5) whether there was a need for
42 specific support measures from the accompanying research project.
43
44
45
46
47
48
49
50

51 *Statistical analysis*

52 Data generated were analysed descriptively using Microsoft Excel. All variables were categorical,
53 hence counts and percentages were computed.
54

55 *Ethical considerations*

56
57
58
59
60

¹ Project website <https://www.begleitforschung-bella.de/en>

1
2
3 All 144 principal investigators of the 174 studies (some lead two or more studies, see above) were
4 asked to give informed consent for data collection and data storage for the accompanying research
5 project, including the consent to (a) be sent an online questionnaire, to (b) have the questionnaire
6 data analysed and saved. 120 principal investigators gave their written consent and were included
7 in the study. All questionnaires were de-identified by an independent trust centre before analysis.
8 The study was approved by the Ethics Committee of the University of Regensburg (19-1630-101).

13 *The online workshop*

14
15 A one-hour online workshop open to all interested investigators from the 'Healthy - for a lifetime'
16 funding programme was held on 28 May 2020 to validate the findings of the survey. Thirty-two
17 investigators participated in the virtual event. They were presented with the results from the
18 survey and asked to discuss them. The workshop was minuted, and the minutes were analysed
19 with regard to (a) confirmation of presented study results, and (b) additional aspects that were
20 brought up in response to the research questions, given changes in COVID-19 mitigation policies
21 that have emerged within the timespan after the survey.

27 **Results**

28 *Sample*

29
30 Out of the 120 investigators who were invited to participate, 93 (78%) completed the
31 questionnaire. 8 responses were excluded from the sample because the projects had already ended
32 and could therefore not have been affected by the pandemic, which led to sample of 85 (71%)
33 questionnaires for analysis.

34
35 All funding areas are represented in the survey, with child and youth health projects most
36 prevalent. The distribution across the different funding areas broadly matches the overall
37 distribution of all funded projects, with gender projects and clinical studies in old age being
38 slightly underrepresented in our sample and healthcare and nursing studies in old age being very
39 slightly overrepresented. A small number of respondents were unsure which funding area their
40 project could be assigned to.

41 *Impact of the COVID-19 pandemic on research*

42
43 The vast majority of investigators reported that their projects were at least partially affected by the
44 pandemic, either because implementation was being impeded through the crisis (84%), or because
45 it was suspended (18%) (Figure 1).
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Figure 1: Perceived effects of the COVID-19 pandemic on project implementation, N=85,
4 multiple answers possible
5

6
7 Those respondents who reported an effect on project implementation (93%), were asked for the
8 causes (Figure 2). The most frequently cited barriers to continuing research projects were
9 difficulties in data collection procedures (80%), and failure to implement planned interventions
10 (67%). Also, staff shortages due to the pandemic were reported, e.g. due to child care
11 commitments during the lockdown resulting from the closure of child care facilities or because of
12 elder care commitments (38%), due to COVID-19 quarantine and disease (11%) or because all
13 project work had been suspended because of official instructions (14%) or because staff had been
14 assigned to other tasks, e.g. clinical work (9%).
15
16
17
18
19
20
21
22

23 Figure 2: Causes of research impediments, N=79, multiple answers possible
24

25 Additional free text responses indicated further problems with recruitment of study participants,
26 which proved more difficult during the pandemic, had been put on hold or ended ahead of time (n
27 = 4). Data collection was described as being more difficult or of lower quality (n=3). Practical
28 adjustments such as shifting tasks between project partners, working from home and virtual
29 meetings replacing travel were also reported (n=6), while others cited difficulties caused by
30 working from home, which included access to data or technical infrastructures (n=2). Lacking
31 possibilities of validating findings through conference presentations were also mentioned (n=1)
32
33 The COVID 19 pandemic also impacted on scientific outputs and academic careers; for example,
34 more than half of participants stated that publications were delayed or could not be realised
35 (56%). Difficulties with continuing PhD and master's theses were also reported (18%). Figure 3
36 shows more details.
37
38
39
40
41
42
43
44
45

46 Figure 3: Influence of the pandemic on scientific and/or academic progress, N=85, multiple
47 answers possible
48

49
50 The majority of researchers have reacted to the restrictions caused by the pandemic with
51 mitigation strategies. They modified their data collection methods (46%, e.g. by employing
52 Internet-based access to study participants) or made adjustments in project implementation (46%).
53 In some projects, the research concept including the research questions were adjusted, sometimes
54 to include COVID-19 related topics (27%). However, some investigators (18%) had not employed
55 mitigation strategies in their projects yet, sometimes because the measures mentioned above were
56 not feasible for their projects. See Figure 4 for more details.
57
58
59
60

1
2
3
4
5 Figure 4: Mitigation strategies used to deal with restrictions caused by the pandemic, N=85,
6 multiple answers possible
7
8

9 In terms of support requirements, some researchers expressed an interest in sharing know-how
10 with the other funded projects about digital communication tools (21%) and enabling participation
11 digitally, e.g. in terms of organisational and moderation skills (19%). This is presented in Figure
12 5.
13
14
15

16
17
18 Figure 5: Need for support from the accompanying research project, N=86, multiple answers
19 possible
20
21

22 *Validation through online workshop*

23
24 The discussions documented during the workshop confirmed the survey results and highlighted
25 the immense effect the pandemic has had on many health research projects not related to COVID-
26 19. Concerns were raised about the ability to re-start interventions, for example in the case of
27 workplace interventions when staff were working remotely or were on reduced hours.
28
29

30
31 Investigators of projects that were able to continue implementation were concerned about the
32 validity of their research in the face of deviations from study protocols that had been necessary
33 during the pandemic. It was also pointed out that some projects, e.g. about mental health, had
34 defined patient endpoints such as loneliness and depression, which were now severely affected by
35 the pandemic, so the comparability of the data to earlier results may be reduced.
36
37
38

39
40 Organisational issues regarding data collection and implementation of interventions during the
41 pandemic were raised, e.g. the need to inform participants about risk of infection, hygiene
42 requirements or liability. Difficulties of elderly participants with online data collection were
43 reported as a further practical challenge.
44
45
46
47
48
49

50 **Discussion**

51 *Principal findings*

52
53 Our findings show that the COVID-19 pandemic has had a severe impact on the vast majority of
54 93 heterogeneous health research projects of the “Healthy - for a lifetime” funding programme.
55
56 The programme is not related to COVID-19 research, and most projects were unable to continue
57 their work as planned. They were impeded in their recruitment of participants, implementation of
58
59
60

1
2
3 interventions or data collection. A lack of staff availability due to private or other professional
4 commitments or as a result of COVID-19 quarantine or illness were also observed by half of the
5 investigators surveyed. Several participants reported that projects had to be suspended
6 temporarily, and at the time of the survey, it was not clear whether they could be resumed in the
7 near future. Investigators were creative in developing mitigation strategies for restrictions in data
8 collections, with many drawing on digital communication, but this was not an option for all
9 projects. A quarter of participants stated that they bridged the imposed suspension in their projects
10 by adjusting their research, including pursuing novel COVID-19-related research. Investigators
11 also expressed a need for exchange on digital communication as well as guidance regarding issues
12 such as hygiene and participation. Methodological issues related to deviation from study protocols
13 or validity of mid-study changes in data collection methods. This also raised concerns as to
14 whether the data would eventually qualify for publication and further scientific exploitation, or
15 whether they would ultimately need to be abandoned.

25 *Our findings in the context of other studies*

26
27 To date, only few other studies have examined the impact of the pandemic on non-COVID-19
28 health research. Their results, by and large, correspond to our findings. A survey of 1,212
29 university health researchers by Research Australia found similar rates of investigators reporting
30 that their research was affected by the pandemic (79.6%). The mentioned difficulties referred to
31 participant recruitment in trials (49.3%), working remotely (51.2%) and access to equipment,
32 supplies and materials (28.4%). In this Australian study, the researchers also frequently
33 anticipated delays in project implementation (88.7%) and publications (80.9%) (20). Other
34 surveys focused on particular areas of health research. In April 2020, a European survey of 184
35 eating disorder researchers found that about half of respondents had moved at least part of their
36 research to online settings; only 14% did not expect COVID-19 to induce changes in their future
37 research practices, whereas 30% expected to make such changes (57% indicated that it was "too
38 soon to tell") (20).

47 *Meaning of study and implications for policy and practice*

48
49 Commentators agree that the pandemic will affect research for a long time to come (21–23). Due
50 to the ongoing need for social distancing, personal contact with study participants and therefore
51 resumption of regular data collection and implementation of interventions is likely to remain
52 difficult. The delay of outputs from non-COVID research can lead to a lack of progress in fields
53 of health research that lack the urgency of COVID but nonetheless take a significant toll human
54 health (22). Also, there is the risk of new waves of infections and either local or general lock-
55 downs due to SARS-CoV-2, but possibly in the future also due to other pandemics. Therefore,
56
57
58
59
60

1
2
3 future strategies for planning, implementing and funding health research need to incorporate the
4 possibility of potential disruptions and restrictions inflicted by pandemics and infection control
5 measures. The importance of research, especially in crisis situations, as well as the need for new
6 paradigms and models of resilient and efficient research has been highlighted in the literature (24,
7 25). Therefore, it seems important to not only handle the current challenges, but also to plan for
8 long-term approaches preventing or taking into consideration these challenges for future research.
9 Our study raises the following important questions: a) How can progress made with participation
10 in health research be maintained despite difficulties and uncertainties about the future? b) How
11 can resilience be built into study protocols to ensure that they can be adapted if necessary and data
12 already collected is not lost, and at the same time protocols remain methodologically robust? c)
13 How can different intervention and data collection methods be meaningfully combined and biases
14 introduced be accounted for? d) How can funding instruments be designed to accommodate
15 changes more easily and, e) How can funders support investigators during crises such as
16 pandemics?
17
18
19
20
21
22
23
24
25

26
27 The pandemic is currently changing the way scientific knowledge is being produced (26), in fact it
28 is accelerating a trend that has already been underway: The use of digital tools had been
29 increasing gradually (27–29), and during the pandemic, with often no other alternatives being
30 available, it has surged (30). While the pandemic undeniably poses many challenges to health
31 research projects, its silver lining may be a chance to make a leap in digital communication and
32 participation as well as better resilience at both the research and the funding side. This should be
33 accompanied by a thorough investigation of the strengths and weaknesses as well as the
34 comparability of different tools for interventions and data collection methods. Existing findings
35 on the comparison of analogue and digital data collection methods are sparse and limited in scope,
36 but so far indicate that there are no far-reaching differences (31–36). More research is required
37 regarding issues such as acceptance, reach and over-/ underrepresentation of different groups,
38 usability in different settings and for different topics. During data analysis, the influence of
39 changes in collection methods and other deviations from study protocols as well as missing
40 information need to be considered. Descriptions should delineate which of these irregularities are
41 likely to be a result of the COVID-19 pandemic and which uncertainties remain (37).
42
43
44
45
46
47
48
49
50

51
52 Funders should consider granting extensions to projects if these face delays because of the
53 pandemic, and allow for adjustments in research design and research questions, as has already
54 happened in the case of many funders (38). Changes to funding itself may also be needed. To
55 prepare for ongoing restrictions, further lockdowns or other pandemics, policy makers and funders
56 could introduce more flexible funding instruments. Research that generates evidence about the
57 validity and scientific rigour of digital methods or about the combination of digital and traditional
58
59
60

1
2
3 methods will be needed to accompany the shift to a “new normality” in research, and it will also
4 be a task for policy makers to ensure research priorities are set accordingly.
5
6

7 Researchers will be required to continue experimenting with new approaches, assessing their
8 usefulness, reflecting on their findings and sharing their insights. The scientific community at
9 large will have to deal with results of research that have taken place under different circumstances
10 than usual, and maybe with methodologic compromises. Consensus will be needed about how
11 these findings can be meaningfully integrated with other scientific outcomes, both in terms of
12 comparison to existing findings and in terms of research validation. Ultimately, it is a joint
13 responsibility of policy makers, researchers, health professionals and funders to ensure that
14 research funding is spent efficiently and effectively. The pandemic has changed the way in which
15 scientific knowledge is produced, and some of the changes may be permanent, which will
16 ultimately require adaptations to what constitutes good scientific practice.
17
18
19
20
21
22

23 *Strengths and weaknesses*

24
25
26 Evidence on the impact of COVID-19 on ongoing health research projects is still scarce. Initial
27 findings from other surveys confirm the results of our study. We used a representative sample of
28 heterogeneous projects from the “Healthy - for a lifetime” funding programme in Germany,
29 therefore giving important insights into the impact on health research in general. However, the
30 study only presents a snapshot of the situation in May 2020, and captured the experiences of a
31 limited number of investigators. Due to the dynamics in the COVID-19 pandemic and infection
32 control measures, restrictions in project work and data collection processes vary significantly over
33 time. Therefore, it would be helpful to repeat the survey at certain intervals. As the pandemic has
34 been imposing ongoing challenges on health research, with mitigation strategies and social
35 distancing regulations being present for months, further surveys, e.g. after six or twelve months,
36 may reflect impact on projects even better and capture lessons learnt by project investigators.
37
38
39
40
41
42
43

44
45 The research projects included in the study covered a wide range of topics, addressed target
46 groups, and study types. However, due to the overall focus of the funding programme, there was a
47 predominance of intervention projects in prevention and health services research; biomedical
48 research accounted for only a minority of projects. Among biomedical, laboratory-based studies,
49 regulations about social distancing may have a different influence (e.g. by rendering access to labs
50 difficult, rather than preventing contact to patients or participants). Still, our survey results
51 highlight the range and extent of challenges imposed upon health research.
52
53
54
55
56
57
58
59
60

Conclusions

1
2
3 The disruption of health research projects caused by the COVID-19 pandemic has been severe and
4 calls for short-term measures to limit damage to projects and to participation in health research in
5 general, but also the development of long-term strategies to improve the resilience of research
6 against imponderables posed by pandemics. Both require flexibility from policy makers, funders
7 and researchers as well as insights and guidance from the scientific community.
8
9
10
11
12
13

14 **What is already known on this topic**

- 16 • To date, empirical evidence on the impact of the COVID-19 pandemic on ongoing health
17 research projects is scarce. Other studies have identified a significant disruption of health
18 research.
19
20
21

22 **What this study adds**

- 24 • The study sheds light on how ongoing health research projects in Germany have been
25 affected by the COVID-19 pandemic. It also investigates what mitigation strategies have
26 been put in place, what issues could not be resolved and what challenges and opportunities
27 the current situation holds for policy makers, funders, researchers and the scientific
28 community at large.
29
30
31
32
33
34

35 **Footnotes**

37 **Contributors** TB, JL, CA, HA and JR designed the study. TB led its implementation and together
38 with JL wrote the initial draft of the article. NB carried out the initial analysis of the data and all
39 authors were involved in further analysis. LB contributed insights from the recent literature. All
40 authors contributed to subsequent manuscript revisions and approved its publication.
41
42

43 **Funding** This work was supported by the German Ministry of Education and Research, grant
44 number 01GL1905B.
45
46

47 **Competing interests** None declared.
48

49 **Ethical approval** University of Regensburg Ethical Committee (19-1630-101).
50
51

52 **Data sharing statement** No additional data are available.
53
54

55 **Transparency declaration** TB affirms that the manuscript is an honest, accurate, and transparent
56 account of the study being reported; that no important aspects of the study have been omitted; and
57 that any discrepancies from the study as planned (and, if relevant, registered) have been
58 explained.
59
60

1
2
3 Dissemination to participants and related patient and public communities: Preliminary findings
4 have already been shared and discussed with investigators from the “Healthy - for a lifetime”
5 funding programme. The publication will also be disseminated among this group, the funding
6 body and beyond.
7

8
9 A preprint of this manuscript has been deposited at <https://www.medrxiv.org/>.

10
11 **Licence** The Corresponding Author has the right to grant on behalf of all authors and does grant
12 on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all
13 forms, formats and media (whether known now or created in the future), to i) publish, reproduce,
14 distribute, display and store the Contribution, ii) translate the Contribution into other languages,
15 create adaptations, reprints, include within collections and create summaries, extracts and/or,
16 abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution,
17 iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the
18 Contribution to third party material where-ever it may be located; and, vi) licence any third party
19 to do any or all of the above.
20
21
22
23
24
25
26
27


28 **References**

- 29
30 1. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G et al. COVID-19: towards
31 controlling of a pandemic. *The Lancet* 2020; 395(10229):1015–8.
32
- 33 2. WHO. Transmission of SARS-CoV-2: implications for infection prevention precautions: Scientific
34 Brief; 2020 [cited 2020 Jul 30]. Available from: URL: [https://www.who.int/news-](https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions)
35 [room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-](https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions)
36 [precautions](https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions).
37
- 38 3. Zhang SX, Wang Y, Rauch A, Wei F. Unprecedented disruption of lives and work: Health, distress
39 and life satisfaction of working adults in China one month into the COVID-19 outbreak. *Psychiatry Res*
40 2020; 288:112958.
41
- 42 4. Walensky RP, Del Rio C. From Mitigation to Containment of the COVID-19 Pandemic: Putting the
43 SARS-CoV-2 Genie Back in the Bottle. *JAMA* 2020.
44
- 45 5. Zhang Y, Ma ZF. Impact of the COVID-19 Pandemic on Mental Health and Quality of Life among
46 Local Residents in Liaoning Province, China: A Cross-Sectional Study. *Int J Environ Res Public Health*
47 2020; 17(7).
48
- 49 6. Cluver L, Lachman JM, Sherr L, Wessels I, Krug E, Rakotomalala S et al. Parenting in a time of
50 COVID-19. *The Lancet* 2020; 395(10231):e64.
51
- 52 7. Kambhampati SBS, Vaishya R, Vaish A. Unprecedented surge in publications related to COVID-19 in
53 the first three months of pandemic: A bibliometric analytic report. *J Clin Orthop Trauma* 2020.
54
- 55 8. Omary MB, Eswaraka J, Kimball SD, Moghe PV, Panettieri RA, Scotto KW. The COVID-19 pandemic
56 and research shutdown: staying safe and productive. *J Clin Invest* 2020.
57
- 58 9. Graham MM, Higginson L, Brindley PG, Jetly R. Feel Better, Work Better: The COVID-19
59 Perspective. *Can J Cardiol* 2020.
60


10. Callard F, Rose D, Wykes T. Close to the bench as well as at the bedside: involving service users in all phases of translational research. *Health Expect* 2012; 15(4):389–400.
11. Tremblay M-C, Richard L. Complexity: a potential paradigm for a health promotion discipline. *Health Promot Int* 2014; 29(2):378–88.
12. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ* 2008; 337:a1655.
13. Bressan V, Bagnasco A, Aleo G, Timmins F, Barisone M, Bianchi M et al. Mixed-methods research in nursing - a critical review. *J Clin Nurs* 2017; 26(19-20):2878–90.
14. Willis R, Evandrou M, Pathak P, Khambhaita P. Problems with measuring satisfaction with social care. *Health Soc Care Community* 2016; 24(5):587–95.
15. Inouye DW, Underwood N, Inouye BD, Irwin RE. Support early-career field researchers. *Science* 2020; 368(6492):724–5.
16. Staniscuaski F, Reichert F, Werneck FP, Oliveira L de, Mello-Carpes PB, Soletti RC et al. Impact of COVID-19 on academic mothers. *Science* 2020; 368(6492):724. Available from: URL: <https://science.sciencemag.org/content/368/6492/724.1?fbclid=IwAR31Qq-VYfKlbrA3MrbH-7lrzCl4KvnpdFYdbgP0rO8wccoMtZHDN6-jyys>.
17. Alon T, Doepke M, Olmstead-Rumsey J, Tertilt M. *The Impact of COVID-19 on Gender Equality*. Cambridge, MA; 2020.
18. Wang X, Di Liu, Ding K, Wang X. Science funding and research output: a study on 10 countries. *Scientometrics* 2012; 91(2):591–9.
19. Federal Ministry of Health. Health Research [cited 2020 Aug 5]. Available from: URL: <https://www.bmbf.de/en/health-research-2308.html>.
20. Weissman RS, Klump KL, Rose J. Conducting eating disorders research in the time of COVID-19: A survey of researchers in the field. *Int J Eat Disord* 2020; 53(7):1171–81.
21. Tuttle KR. Impact of the COVID-19 pandemic on clinical research. *Nat Rev Nephrol* 2020 [cited 2021 Apr 27]; 16(10):562–4. Available from: URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404075/pdf/41581_2020_Article_336.pdf.
22. Yanow SK, Good MF. Nonessential Research in the New Normal: The Impact of COVID-19. *Am J Trop Med Hyg* 2020 [cited 2021 Oct 20]; 102(6):1164–5.
23. Sohrabi C, Mathew G, Franchi T, Kervan A, Griffin M, Soleil C Del Mundo Jennick et al. Impact of the coronavirus (COVID-19) pandemic on scientific research and implications for clinical academic training – A review. *International Journal of Surgery* 2021 [cited 2020 Nov 26]; 86(87):57–63. Available from: URL: <https://doi.org/10.1016/j.ijsu.2020.12.008>.
24. Weiner DL, Balasubramaniam V, Shah SI, Javier JR. COVID-19 impact on research, lessons learned from COVID-19 research, implications for pediatric research. *Pediatr Res* 2020; 88(2):148–50.
25. Richardson SJ, Carroll CB, Close J, Gordon AL, O'Brien J, Quinn TJ et al. Research with older people in a world with COVID-19: identification of current and future priorities, challenges and opportunities. *Age Ageing* 2020; 49(6):901–6.
26. Bayram M, Springer S, Garvey CK, Özdemir V. COVID-19 Digital Health Innovation Policy: A Portal to Alternative Futures in the Making. *OMICS* 2020 [cited 2020 Jul 16].

- 1
2
3 27. Lo Iacono V, Symonds P, Brown DH. Skype as a Tool for Qualitative Research Interviews. *Sociological Research Online* 2016; 21(2):103–17.
4
5
6 28. Archibald MM, Ambagtsheer RC, Casey MG, Lawless M. Using Zoom Videoconferencing for
7 Qualitative Data Collection: Perceptions and Experiences of Researchers and Participants.
8 *International Journal of Qualitative Methods* 2019; 18:160940691987459.
9
10 29. Korbel JO, Stegle O. Effects of the COVID-19 pandemic on life scientists. *Genome Biol* 2020;
11 21(1):113.
12
13 30. Lupton D. Doing fieldwork in a pandemic (crowd-sourced document); 2020 [cited 10.8.20].
14 Available from: URL:
15 <https://docs.google.com/document/d/1clGjGABB2h2qbduTgfqribHmog9B6P0NvMgVuiHZCl8/edit?ts=5e88ae0a#>.
16
17
18 31. Belisario MJ, Jamsek J, Huckvale K, O'Donoghue J, Morrison CP, Car J. Comparison of self-
19 administered survey questionnaire responses collected using mobile apps versus other methods.
20 *Cochrane Database Syst Rev* 2015 [cited 2020 Jul 16]; (7):MR000042.
21
22 32. Barentsz MW, Wessels H, van Diest PJ, Pijnappel RM, Haaring C, van der Pol CC et al. Tablet, web-
23 based, or paper questionnaires for measuring anxiety in patients suspected of breast cancer:
24 patients' preferences and quality of collected data. *J Med Internet Res* 2014 [cited 2020 Jul 16];
25 16(10):e239.
26
27 33. Gwaltney CJ, Shields AL, Shiffman S. Equivalence of electronic and paper-and-pencil
28 administration of patient-reported outcome measures: a meta-analytic review. *Value Health* 2008
29 [cited 2020 Jul 16]; 11(2):322–33.
30
31 34. Morison T, Gibson AF, Wigginton B, Crabb S. Online Research Methods in Psychology:
32 Methodological Opportunities for Critical Qualitative Research. *Qualitative Research in Psychology*
33 2015 [cited 2020 Jul 16]; 12(3):223–32.
34
35 35. Janghorban R, Latifnejad Roudsari R, Taghipour A. Skype interviewing: the new generation of
36 online synchronous interview in qualitative research. *Int J Qual Stud Health Well-being* 2014 [cited
37 2020 Jul 16]; 9:24152.
38
39 36. Touvier M, Méjean C, Kesse-Guyot E, Pollet C, Malon A, Castetbon K et al. Comparison between
40 web-based and paper versions of a self-administered anthropometric questionnaire. *Eur J Epidemiol*
41 2010 [cited 2020 Jul 16]; 25(5):287–96.
42
43 37. Fleming TR, Labriola D, Wittes J. Conducting Clinical Research During the COVID-19 Pandemic:
44 Protecting Scientific Integrity. *JAMA* 2020 [cited 2020 Jul 16].
45
46 38. Stoye E. How research funders are tackling coronavirus disruption. *Nature* 2020.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




For peer review only




For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



For peer review only

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses

Continued on next page

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.